Berta Camps Bisbal, CBD-Intel’s senior legal analyst, presented a comparative analysis of state laws in the US at CBD Live during VOXPO – Virtual Online Vape & CBD Expo on 18th November. She presented an overview of the federal farm bill as well as CBD at the federal level versus state level. You can now […]
Concerns over traceability, limiting final use and demonstrating safety of final products could make it difficult to grant UK novel food approval to CBD ingredients producers and white label manufacturers
CBD-Intel managing director, Tim Phillips, discusses the main facts and issues surrounding CBD and Novel Food status in European markets. He presents the key aspects of the delay, the political issues and the impacts released on the European level and the future challenges for the sector.
Enforcement activity against food, drink and dietary supplement products placed on the market containing CBD continues despite the inability of companies to proceed with novel food applications due to the EC’s questions over whether CBD constitutes a narcotic under the 1961 UN Single Convention on Narcotics.
Several major developments have all happened at the same time for novel foods. Perhaps most importantly, one of the European Commission’s departments – the Directorate-General for Health and Food Safety – has said it is holding sending any further non-synthetic CBD applications to the European Food Safety Authority for evaluation until it has determined whether CBD technically falls under the definition of a narcotic according to the 1961 UN Single Convention on Narcotic Drugs.
Progress on novel food authorisations for non-synthetic cannabinoids will be paused until European regulators decide whether extracts from hemp flowers constitute a drug under narcotics laws, CBD-Intel has learned
A new line of sparkling CBD drinks is to be launched in the Colorado market in what may be an indication of how high-profile companies approach the CBD market during its continued period of uncertainty
Scotland has not followed the rest of the UK in setting a deadline for novel food applications, while the Republic of Ireland has adopted an even more conservative approach, stating that unauthorised novel foods should not be on the market at all
Companies selling foods containing CBD appear to be ignoring the UK Food Standards Agency (FSA)’s latest warning about the EU’s novel foods legislation – because, some of them claim, it has no legal weight
The CBD industry navigates a complex and changing regulatory landscape across the world, with parts of the industry operating in a grey area. This is particularly the case for one of the most popular product categories on the market: edibles
The Centre for Medical Cannabis is launching a new Association for the Cannabinoid Industry (ACI), claiming to be the first CBD trade organisation in the UK to ensure compliance with EU novel food regulations
Companies can advertise food and drinks as containing CBD, however, they should be careful about implying any link to illicit drugs like cannabis, according to the UK Advertising Standards Authority (ASA)
The launch of many CBD-containing foods, beverages and cosmetics in California has been delayed further as a bill legalising their sale is now not expected to pass before the end of the legislative session, which ends on on 13th September
Interest and investment in CBD beverages continues to grow despite some criticism of cannabis drinks in general; so far, the industry has struggled to get oil-based cannabinoids into water-based beverages without issues. But all of that is changing, rapidly…
No food item should contain any cannabinoid, including CBD, in the EU without prior novel food ingredient authorisation following a change by European authorities – though this is open to interpretation
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.
Regulatory report: medical and recreational cannabis – a global overview
CBD-Intel has compiled and classified the regulatory data on medical and recreational cannabis in 50 jurisdictions around the world.
The report, accompanied by a more detailed database, provides an overview of the regulatory situation in the selected countries using maps, and assesses the likelihood that the status quo may change in the future.